Baidu
map

J Clin Oncol:ABVD化疗后获得完全代谢缓解的晚期霍奇金淋巴瘤患者可安全省略巩固化疗

2020-09-22 MedSci原创 MedSci原创

HD 0607试验(NCT00795613)旨在研究巩固放疗(cRT)用于初始有大淋巴结(LNM)的经阿霉素、博来霉素、长春碱和达卡巴嗪(ABVD)化疗后获得完全代谢缓解的晚期霍奇金淋巴瘤(cHL)的

HD 0607试验(NCT00795613)旨在研究巩固放疗(cRT)用于初始有大淋巴结(LNM)的经阿霉素、博来霉素、长春碱和达卡巴嗪(ABVD)化疗后获得完全代谢缓解的晚期霍奇金淋巴瘤(cHL)的作用。

招募晚期 (IIB-IVB)HL患者,要求基线有LNM(淋巴结最大直径≥ 5 cm),两次和六次ABVD化疗后PET检查(PET-2和PET-6)均为阴性。受试患者被随机分至两组,接受cRT或不再进一步治疗(NET)。


(研究流程)

在296位随机分组的患者中,101位患者的基线LNM最大直径在5-7 cm(A亚组),96位的在8-10 cm(B亚组),另外99位的为典型肿块(直径> 10 cm,C亚组)。280位(88%)患者表现出化疗后RM。cRT的中位剂量为30.6 Gy(范围 24-36 Gy)。


(三个亚组不同治疗情况的无进展存活期[PFS])

中位随访5.9年后,A亚组中接受cRT或NET的患者的6年无进展存活率分别是91%(95% CI 84%-99%)和95%(895-100%);B亚组中的分别是98%(93%-100%)和90%(80%-100%);C亚组中的分别是89%(81%-98%)和86%(77%-96%)。

综上所述,PET-2和PET-6检查均为阴性的HL患者,可不进行巩固化疗,对存活预后无明显影响,不论确诊时的淋巴结有多大。

原始出处:

Andrea Gallamini, et al. Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. Journal of Clinical Oncology. September 18, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1057491, encodeId=3caa105e491b7, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220121/3f330f5120674454867bac0feecc87e2/d9b4fca813a64858890939f98194bcb9.jpg, createdBy=a1292472119, createdName=ms3263590422704434, createdTime=Mon Oct 04 14:01:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043684, encodeId=b5ed20436842e, content=<a href='/topic/show?id=99ee1e88e3' target=_blank style='color:#2F92EE;'>#ABVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1788, encryptionId=99ee1e88e3, topicName=ABVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Feb 11 15:51:34 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865912, encodeId=82601865912af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 29 18:51:34 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043064, encodeId=7af5204306444, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Wed Dec 30 07:51:34 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887598, encodeId=8d1488e598d2, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>淋巴瘤希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 23 10:01:11 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887516, encodeId=f48488e516b9, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>应该不难搞定了, beContent=null, objectType=article, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Sep 22 22:08:23 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038114, encodeId=d8c910381142d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Tue Sep 22 20:51:34 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2021-10-04 ms3263590422704434

    有收获

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1057491, encodeId=3caa105e491b7, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220121/3f330f5120674454867bac0feecc87e2/d9b4fca813a64858890939f98194bcb9.jpg, createdBy=a1292472119, createdName=ms3263590422704434, createdTime=Mon Oct 04 14:01:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043684, encodeId=b5ed20436842e, content=<a href='/topic/show?id=99ee1e88e3' target=_blank style='color:#2F92EE;'>#ABVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1788, encryptionId=99ee1e88e3, topicName=ABVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Feb 11 15:51:34 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865912, encodeId=82601865912af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 29 18:51:34 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043064, encodeId=7af5204306444, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Wed Dec 30 07:51:34 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887598, encodeId=8d1488e598d2, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>淋巴瘤希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 23 10:01:11 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887516, encodeId=f48488e516b9, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>应该不难搞定了, beContent=null, objectType=article, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Sep 22 22:08:23 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038114, encodeId=d8c910381142d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Tue Sep 22 20:51:34 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2021-02-11 yangfl06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1057491, encodeId=3caa105e491b7, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220121/3f330f5120674454867bac0feecc87e2/d9b4fca813a64858890939f98194bcb9.jpg, createdBy=a1292472119, createdName=ms3263590422704434, createdTime=Mon Oct 04 14:01:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043684, encodeId=b5ed20436842e, content=<a href='/topic/show?id=99ee1e88e3' target=_blank style='color:#2F92EE;'>#ABVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1788, encryptionId=99ee1e88e3, topicName=ABVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Feb 11 15:51:34 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865912, encodeId=82601865912af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 29 18:51:34 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043064, encodeId=7af5204306444, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Wed Dec 30 07:51:34 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887598, encodeId=8d1488e598d2, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>淋巴瘤希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 23 10:01:11 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887516, encodeId=f48488e516b9, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>应该不难搞定了, beContent=null, objectType=article, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Sep 22 22:08:23 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038114, encodeId=d8c910381142d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Tue Sep 22 20:51:34 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-29 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1057491, encodeId=3caa105e491b7, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220121/3f330f5120674454867bac0feecc87e2/d9b4fca813a64858890939f98194bcb9.jpg, createdBy=a1292472119, createdName=ms3263590422704434, createdTime=Mon Oct 04 14:01:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043684, encodeId=b5ed20436842e, content=<a href='/topic/show?id=99ee1e88e3' target=_blank style='color:#2F92EE;'>#ABVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1788, encryptionId=99ee1e88e3, topicName=ABVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Feb 11 15:51:34 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865912, encodeId=82601865912af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 29 18:51:34 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043064, encodeId=7af5204306444, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Wed Dec 30 07:51:34 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887598, encodeId=8d1488e598d2, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>淋巴瘤希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 23 10:01:11 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887516, encodeId=f48488e516b9, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>应该不难搞定了, beContent=null, objectType=article, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Sep 22 22:08:23 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038114, encodeId=d8c910381142d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Tue Sep 22 20:51:34 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1057491, encodeId=3caa105e491b7, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220121/3f330f5120674454867bac0feecc87e2/d9b4fca813a64858890939f98194bcb9.jpg, createdBy=a1292472119, createdName=ms3263590422704434, createdTime=Mon Oct 04 14:01:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043684, encodeId=b5ed20436842e, content=<a href='/topic/show?id=99ee1e88e3' target=_blank style='color:#2F92EE;'>#ABVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1788, encryptionId=99ee1e88e3, topicName=ABVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Feb 11 15:51:34 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865912, encodeId=82601865912af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 29 18:51:34 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043064, encodeId=7af5204306444, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Wed Dec 30 07:51:34 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887598, encodeId=8d1488e598d2, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>淋巴瘤希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 23 10:01:11 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887516, encodeId=f48488e516b9, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>应该不难搞定了, beContent=null, objectType=article, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Sep 22 22:08:23 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038114, encodeId=d8c910381142d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Tue Sep 22 20:51:34 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1057491, encodeId=3caa105e491b7, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220121/3f330f5120674454867bac0feecc87e2/d9b4fca813a64858890939f98194bcb9.jpg, createdBy=a1292472119, createdName=ms3263590422704434, createdTime=Mon Oct 04 14:01:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043684, encodeId=b5ed20436842e, content=<a href='/topic/show?id=99ee1e88e3' target=_blank style='color:#2F92EE;'>#ABVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1788, encryptionId=99ee1e88e3, topicName=ABVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Feb 11 15:51:34 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865912, encodeId=82601865912af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 29 18:51:34 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043064, encodeId=7af5204306444, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Wed Dec 30 07:51:34 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887598, encodeId=8d1488e598d2, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>淋巴瘤希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 23 10:01:11 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887516, encodeId=f48488e516b9, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>应该不难搞定了, beContent=null, objectType=article, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Sep 22 22:08:23 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038114, encodeId=d8c910381142d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Tue Sep 22 20:51:34 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-22 lovetcm

    #霍奇金淋巴瘤#在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来#淋巴瘤#应该不难搞定了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1057491, encodeId=3caa105e491b7, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220121/3f330f5120674454867bac0feecc87e2/d9b4fca813a64858890939f98194bcb9.jpg, createdBy=a1292472119, createdName=ms3263590422704434, createdTime=Mon Oct 04 14:01:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043684, encodeId=b5ed20436842e, content=<a href='/topic/show?id=99ee1e88e3' target=_blank style='color:#2F92EE;'>#ABVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1788, encryptionId=99ee1e88e3, topicName=ABVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Feb 11 15:51:34 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865912, encodeId=82601865912af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Sep 29 18:51:34 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043064, encodeId=7af5204306444, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Wed Dec 30 07:51:34 CST 2020, time=2020-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887598, encodeId=8d1488e598d2, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>淋巴瘤希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=211, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 23 10:01:11 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887516, encodeId=f48488e516b9, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>在ABVD化疗后获得完全代谢缓解,可以免去巩固化疗,说明巩固化疗并没有获益。当然,如果加上免疫治疗的话,未来<a href='/topic/show?id=970e659640a' target=_blank style='color:#2F92EE;'>#淋巴瘤#</a>应该不难搞定了, beContent=null, objectType=article, channel=null, level=null, likeNumber=244, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98909, encryptionId=bf079890912, topicName=霍奇金淋巴瘤), TopicDto(id=65964, encryptionId=970e659640a, topicName=淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Sep 22 22:08:23 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038114, encodeId=d8c910381142d, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Tue Sep 22 20:51:34 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-22 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

J Clin Oncol:霍奇金淋巴瘤患者5年内的健康相关生命质量(HRQoL)

健康相关生命质量(HRQoL)是指在疾病、意外损伤及医疗干预的影响下,测定与个人生活事件相联系的主观健康状态和个体满意度。

男性,反复咳嗽,乏力,请诊断!

男性,反复咳嗽,乏力,请诊断!

Lancet oncol:派姆单抗治疗儿科各类肿瘤的疗效

派姆单抗已被批准用于治疗成人晚期癌症,但尚无派姆单抗用于儿科癌症患者的疗效和安全性的相关信息。现研究人员开展一项1-2期开放性研究,以明确派姆单抗用于晚期小儿癌症推荐的2期剂量、安全性和抗肿瘤活性。从多个国家的30家医院招募6-17岁的黑色素瘤或PD-L1阳性的复发性或难治性实体肿瘤或淋巴瘤患儿,要求Lansky Play/Karnofsky表现状态评分≥50,予以派姆单抗 静脉注射,初始剂量2m

喜讯!中国**靶向CD30的抗体药物偶联物ADCETRIS(brentuximab vedotin)获得批准

武田中国今日宣布,靶向CD30的ADCETRIS(brentuximab vedotin)已获得中国国家药品监督管理局(NMPA)的正式批准。

JSH实践指南:血液恶性肿瘤—Ⅱ淋巴瘤:霍奇金淋巴瘤

2018年日本血液学会(JSH)血液恶性肿瘤—淋巴瘤指南,本文为霍奇金淋巴瘤管理指南,主要涉及各阶段霍奇金淋巴瘤的管理等内容。

Blood:免疫突触成分HLA-II和CD58激活玫瑰花结T细胞

霍奇金肿瘤细胞通过涉及II型HLA和CD58的免疫突触形成与玫瑰花结CD4+T细胞广泛相互作用。

Baidu
map
Baidu
map
Baidu
map